Use of ketolides in combination with other drugs to treat experimental toxoplasmosis | Zendy

Fernanda de Assis Araújo | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Use of ketolides in combination with other drugs to treat experimental toxoplasmosis

Author(s) -

Fernanda de Assis Araújo

Publication year - 1998

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/42.5.665

Subject(s) - atovaquone , toxoplasmosis , clindamycin , toxoplasma gondii , sulfadiazine , medicine , pharmacology , pyrimethamine , combination therapy , antibiotics , microbiology and biotechnology , virology , biology , immunology , malaria , chloroquine , antibody , plasmodium falciparum

Because combination therapy is required to treat human toxoplasmosis, we examined combinations of the ketolides HMR 3004 and HMR 3647 with atovaquone, clindamycin or sulphadiazine in a murine model of toxoplasmosis. An oral dose of 50 mg/kg/day of HMR 3004 protected 30% of mice lethally infected with Toxoplasma gondii. The same dose protected 100% of infected mice when administered in combination with non-protective doses of atovaquone, clindamycin or sulphadiazine. Similar results were noted with 25 mg/kg/day of HMR 3647. These results demonstrate that these drug combinations are highly effective for treating toxoplasmosis in mice.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research